Coherus Oncology (STU:8C5) Cyclically Adjusted Book per Share: €0.46 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8C5 Coherus Oncology Inc STU:8C5
29 GF Score
Price €1.07
GF Value €0.83
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Coherus Oncology Cyclically Adjusted Book per Share?

Coherus Oncology STU:8C5 -6.94% 29 Cyclically Adjusted Book per Share is €0.46 as of Jun. 2026. GuruFocus rates STU:8C5 with a GF Score™ of 29/100 and a GF Value™ of €0.83 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Coherus Oncology's adjusted book value per share for the three months ended in Jun. 2026 was €0.341. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.46 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Coherus Oncology's average Cyclically Adjusted Book Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-10), Coherus Oncology's current stock price is €1.073. Coherus Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €0.46. Coherus Oncology's Cyclically Adjusted PB Ratio of today is 2.33.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Coherus Oncology was 25.94. The lowest was 1.21. And the median was 4.03.


Coherus Oncology  (STU:8C5) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Coherus Oncology's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.073/0.46
=2.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Coherus Oncology was 25.94. The lowest was 1.21. And the median was 4.03.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Coherus Oncology Cyclically Adjusted Book per Share Related Terms


Coherus Oncology Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Coherus Oncology's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus Oncology Cyclically Adjusted Book per Share Chart

Coherus Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.30

Coherus Oncology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.30 0.39 0.46

STU:8C5 vs NAUT, AVXL, SLNCF: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Coherus Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus Oncology Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's Cyclically Adjusted PB Ratio falls into.


STU:8C5
29GF Score
Coherus Oncology Inc STU:8C5
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coherus Oncology Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Coherus Oncology's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.341/333.9520*333.9520
=0.341

Current CPI (Jun. 2026) = 333.9520.

Coherus Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.671 241.428 0.928
201612 0.425 241.432 0.588
201703 1.425 243.801 1.952
201706 0.557 244.955 0.759
201709 0.814 246.819 1.101
201712 0.449 246.524 0.608
201803 -0.024 249.554 -0.032
201806 0.798 251.989 1.058
201809 0.156 252.439 0.206
201812 -0.497 251.233 -0.661
201903 -0.492 254.202 -0.646
201906 -0.051 256.143 -0.066
201909 0.726 256.759 0.944
201912 1.346 256.974 1.749
202003 2.008 258.115 2.598
202006 2.656 257.797 3.441
202009 3.014 260.280 3.867
202012 3.185 260.474 4.083
202103 1.467 264.877 1.850
202106 1.696 271.696 2.085
202109 1.451 274.310 1.766
202112 1.124 278.802 1.346
202203 0.147 287.504 0.171
202206 -0.275 296.311 -0.310
202209 -1.261 296.808 -1.419
202212 -1.645 296.797 -1.851
202303 -2.280 301.836 -2.523
202306 -1.708 305.109 -1.869
202309 -1.147 307.789 -1.244
202312 -1.581 306.746 -1.721
202403 -0.663 312.332 -0.709
202406 -0.678 314.175 -0.721
202409 -0.688 315.301 -0.729
202412 -1.090 315.605 -1.153
202503 -1.464 319.799 -1.529
202506 0.894 322.561 0.926
202509 0.643 324.800 0.661
202512 0.430 324.054 0.443
202603 0.441 330.213 0.446
202606 0.341 333.952 0.341

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.46 mean?
Coherus Oncology (STU:8C5) has a Cyclically Adjusted Book per Share of €0.46 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Coherus Oncology and its competitors.
Is Coherus Oncology's Cyclically Adjusted Book per Share too high?
Coherus Oncology's current Cyclically Adjusted Book per Share is €0.46. Overall, Coherus Oncology has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Cyclically Adjusted Book per Share compare to NAUT and AVXL?
Coherus Oncology's Cyclically Adjusted Book per Share of €0.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current Cyclically Adjusted Book per Share is €0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (STU:8C5) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.83, compared to a current price of €1.07 — trading 29.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is €0.46. Coherus Oncology's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Coherus Oncology (STU:8C5), the current Cyclically Adjusted Book per Share is €0.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (STU:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.07 is trading 29.3% above its estimated GF Value™ of €0.83. GuruFocus considers Coherus Oncology to be Modestly Overvalued.

Key valuation signals for STU:8C5:

  • Cyclically Adjusted Book per Share: €0.46
  • GF Value™: €0.83 vs. price of €1.07 (29.3% above fair value)
  • GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the STU:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Coherus Oncology Business Description

Other Exchanges CHRS:USA8C5:Germany
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
29GF Score

Get the complete analysis for STU:8C5

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.07
Price
€0.83
GF Value